{"id":72274,"date":"2026-08-11T12:55:56","date_gmt":"2026-08-11T04:55:56","guid":{"rendered":"https:\/\/flcube.com\/?p=72274"},"modified":"2026-08-11T12:55:58","modified_gmt":"2026-08-11T04:55:58","slug":"jazz-pharmaceuticals-to-acquire-actio-biosciences-for-up-to-usd-1-32-billion-gaining-first-in-class-kcnt1-ion-channel-inhibitor-abs-1230-for-ultra-rare-epilepsy","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=72274","title":{"rendered":"Jazz Pharmaceuticals to Acquire Actio Biosciences for Up to USD 1.32 Billion, Gaining First\u2011in\u2011Class KCNT1 Ion Channel Inhibitor ABS\u20111230 for Ultra\u2011Rare Epilepsy"},"content":{"rendered":"\n

Jazz Pharmaceuticals (NASDAQ: JAZZ<\/a>)<\/strong> announced that it will acquire Actio Biosciences<\/strong>, a privately held biopharmaceutical company, for an upfront payment of USD 820 million<\/strong> and up to USD 500 million in potential milestone payments<\/strong>, bringing the total transaction value to USD 1.32 billion<\/strong>. The transaction is expected to close in the fourth quarter of 2026<\/strong>.<\/p>\n\n\n\n

Deal Overview<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Acquirer<\/strong><\/td>Jazz Pharmaceuticals (NASDAQ: JAZZ)<\/td><\/tr>
Target<\/strong><\/td>Actio Biosciences (private)<\/td><\/tr>
Upfront Payment<\/strong><\/td>USD 820 million<\/td><\/tr>
Potential Milestone Payments<\/strong><\/td>Up to USD 500 million<\/td><\/tr>
Total Transaction Value<\/strong><\/td>USD 1.32 billion<\/td><\/tr>
Expected Closing<\/strong><\/td>Fourth quarter of 2026<\/td><\/tr>
Key Asset<\/strong><\/td>ABS\u20111230 \u2014 first\u2011in\u2011class KCNT1 ion channel inhibitor for KCNT1+ epilepsy<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Lead Asset Profile \u2013 ABS\u20111230<\/h2>\n\n\n\n
Attribute<\/th>Detail<\/th><\/tr><\/thead>
Molecule<\/strong><\/td>ABS\u20111230<\/td><\/tr>
Class<\/strong><\/td>Novel, first\u2011in\u2011class small molecule precision therapy<\/strong><\/td><\/tr>
Target<\/strong><\/td>KCNT1 ion channel inhibitor<\/strong><\/td><\/tr>
Indication<\/strong><\/td>KCNT1+ epilepsy<\/strong><\/td><\/tr>
Clinical Status<\/strong><\/td>Early clinical proof\u2011of\u2011concept trial in children with KCNT1 epilepsy demonstrated meaningful reductions in seizures<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Disease Background \u2013 KCNT1+ Epilepsy<\/h2>\n\n\n\n